Author: admin

Paradigm Clinical Research Co-Founds New Trade Association to Transform Clinical Trials

Paradigm Clinical Research is proud to co-found the Association of Multisite Research Corporations (AMRC)— a transformative initiative for the clinical trial industry.  January 23, 2025 – Paradigm Clinical Research is proud to announce the launch of the Association of Multisite Research Corporations (AMRC), a transformative initiative for the clinical trial industry. Kurt Mussina, CEO of Paradigm Clinical Research, is a co-founder, highlighting our commitment to advancing the adoption of multisite clinical research corporations (MCRCs) to address long-standing challenges in clinical research. The AMRC brings together 14 industry-leading multisite organizations to establish standardized practices and foster collaboration. This trade association aims to enhance trial execution, improve patient recruitment, and streamline regulatory compliance, ultimately delivering better outcomes for patients and sponsors. Paradigm Clinical Research is honored to be founding members of AMRC in reshaping the clinical research landscape. Together, we are building a more efficient, inclusive, and impactful future for medical innovation. Learn more about the AMRC and register for the upcoming webinar to hear from industry leaders about the future of clinical trials through innovation and collaboration.      

Multiple Site Management Strategies – Amy Henderson Featured in Q&A with International Clinical Trials

Leading Multi-Site Research: Maximizing Efficiency and Reducing Turnover International Clinical Trials, August 2024, pages 95-97. © Samedan Ltd Managing multiple clinical research sites can be challenging, but with the right strategies, it’s entirely achievable. Effective management is key to reducing turnover, streamlining operations, and ensuring smooth research progress across locations. Amy Henderson speaks with International Clinical Trials about how a multi-site research business maximizes efficiency by harnessing challenges as opportunities. Learn best practices for resource allocation, team unification, and technology integration. Discover actionable insights on reducing turnover, standardizing procedures, and creating a motivated, cohesive team. Read Article      

Paradigm Clinical Research Expands into Modesto, Increasing Clinical Trial Opportunities in California’s Critically Underserved Central Valley Corridor

Paradigm Clinical Research announces the opening of its newest clinical research site in Modesto, California. This expansion aligns with our mission to serve communities historically underrepresented in clinical trials.  The Modesto clinic represents another example of Paradigm Clinical Research’s operating playbook and de novo expansion strategy.  Modesto represents a strategic addition to our footprint, aiming to provide access to clinical trials across the Central Valley region. Our decision to establish a presence in Modesto was driven by the area’s demographic diversity and profound lack of any other professionally managed clinical trial businesses. Our goal in Modesto is to create a robust clinical research ecosystem that supports both study sponsors and the local community. The expansion in Modesto complements Paradigm Clinical Research’s long standing clinic further north in Redding, CA and the company’s strategic interests in the intermediate markets including Sacramento and beyond. This development follows our successful clinic openings in Boise, Idaho, and our flagship site in San Diego. It underscores our mission to provide opportunities to advance the human condition through participation in clinical research.

Paradigm Clinical Research Opens Its Flagship Clinic in San Diego, Marking 15 Years of Success

Paradigm Clinical Research, a leading clinical research site business, announced the opening of its flagship clinic in San Diego, California coinciding with the celebration of the company’s 15th anniversary. This is a significant milestone in the company’s growth strategy, positioning its flagship site to better serve the evolving needs of patients and the clinical research community. “The opening of our flagship clinic solidifies Paradigm Clinical Research’s position at the forefront of the multi-location and multi-specialty clinical research site market,” said Kurt Mussina, CEO of Paradigm Clinical Research. “Our operating model is ‘one site offering many locations and investigators,’ meaning all our clinics and staff function under a single, harmonized set of operating standards and principles. This positions us well to deliver industry-leading value to all stakeholders, especially patients, as evidenced by our exceptional patient Net Promoter Score® of 96. The opening of our San Diego clinic not only aligns with a decade and a half of success, but also validates our unique operating and growth strategies.” “We are proud of the success the entire Paradigm Clinical Research team has achieved, including the opening of the company’s flagship clinic,” said Aleem Choudhry, Managing Partner at Crane Street Capital. “This highlights the strength of the team’s managerial and operational expertise, providing the company with an even greater ability to meet the needs of clinical trial sponsors on so many different levels.” Paradigm Clinical Research celebrates its 15th anniversary this year, marking a decade and a half of success supporting industry sponsored clinical trials. The company remains committed to fostering diversity and inclusion and boasts access to a distinguished team of principal investigators across several therapeutic areas and specialties. For more information about Paradigm Clinical Research and its services, please visit paradigm-research.com. About Paradigm Clinical Research Paradigm Clinical Research is a long-standing clinical research site business with locations in California, Colorado, and Idaho. The company operates wholly owned sites that support Phase I-IV clinical trials and provides sponsors with access to diverse and often under-represented patient populations and investigators. Paradigm’s mission is to enrich lives by offering opportunities to advance the human condition through participation in expertly conducted clinical trials. To learn more, please visit paradigm-research.com. About Crane Street Capital Group Crane Street Capital Group specializes in micro growth buyouts in a few selected fragmented industries with untapped white space potential for growth. Its investments target companies that not only have outsized growth potential within their industries but also have the ability to make tremendously positive impacts within the communities in which they operate. Crane Street maintains a concentrated portfolio, deploys capital on an independent basis when outstanding opportunities are available and implements a patient approach in value creation over typically 5+-year holding periods. Currently, there are seven companies in the portfolio, four of which are in education services and three of which are in healthcare services.

Paradigm Clinical Research Expands Into Boise, Idaho, Advancing the Company’s Portfolio of Therapeutic Area Expertise

February 8, 2024 – Paradigm Clinical Research, a leading clinical research site business, announces the opening of its latest clinical research site in Boise, Idaho. This marks a significant milestone as the company establishes its first site in Idaho, further advancing its footprint and its portfolio of therapeutic areas including women’s health studies. This emphasizes Paradigm Clinical Research’s commitment to making meaningful differences in the lives of the individuals and communities the company serves. The Boise site complements the company’s existing locations, reinforcing Paradigm Clinical Research’s dedication to establishing purpose-built research sites that cater to the growing demand for study participants and the crucial need for diverse populations and investigators. The expansion in Boise includes the company’s growing roster of partner investigators, including Dr. Keri Erland, Dr. Kelly Siudzinski, Dr. Tara Erbele, and Dr. Roger Wyatt, all playing pivotal roles in bringing clinical trial opportunities to the greater Treasure Valley community. Kurt Mussina, CEO of Paradigm Clinical Research, emphasized the unique aspect of this expansion, stating, “Boise represents more than a geographic extension for us; it’s an opportunity to make further strides in women’s health and our other therapeutic areas of interest. We are not merely opening a new location; we are expanding our commitment to advancing healthcare, particularly in areas that matter most to the community.” Paradigm Clinical Research’s newest clinical research site is located at 959 S. Allante Place, Boise, ID, 83709. Get Directions to Paradigm Clinical Research in Boise, ID Learn more about participating in a clinical study or becoming a principal investigator.        

San Diego NBC 7 Cytomegalovirus (CMV) Article

Cytomegalovirus (CMV) is making headlines, and it’s behind a majority of US birth defects. The virus spreads through fluids, making it a serious concern for expectant parents. As we uncover more about this alarming situation, it’s crucial to stay informed and take necessary precautions to protect ourselves and our loved ones. Watch or read more in San Diego NBC 7’s “‘It’s spread with fluids’: Little-known virus behind majority of US birth defects” article. Paradigm Clinical Research is currently enrolling participants for a CMV vaccine study. Submit a form to learn more by filling out our join a study form. Knowledge is power, and understanding the risks empowers us to make informed decisions. Let’s share this important article to raise awareness and support clinical research efforts to combat this health challenge. Together, we can strive for a safer and healthier future for generations to come. Because Better Medicines Matter More Than Ever.

Paradigm Clinical Research Announces Expansion of Site Locations

Company Doubles Commitment in Denver Market with Additional Clinical Research Site REDDING, California; April 18, 2023 – Paradigm Clinical Research, a leading clinical research site business, announces the opening of its clinical research site in Littleton, Colorado, the company’s fourth location. The new site location complements the company’s long-standing site in Wheat Ridge, Colorado. This expansion is a continuation of Paradigm Clinical Research’s growth strategy, which focuses on creating purpose-built research sites to fulfill the industry’s demand for study participants and the critical need for diverse populations and investigators. As part of this strategy, the company has partnered with Andy Fine, M.D., who will serve as a principal investigator (PI) in Littleton. Dr. Fine is a primary care physician at Colorado Primary Health Care, which is the leading primary care group in the area, serving a large and diverse patient base. “We are thrilled to expand Paradigm Clinical Research’s reach in the Denver market and are excited about our partnership with Dr. Fine and other physician specialists in the area. Our mission is to provide the communities we serve with opportunities to advance the human condition through participation in expertly conducted clinical trials,” said Kurt Mussina, CEO of Paradigm Clinical Research. “I became a principal investigator because I want to be at the forefront of medical advancements that can have a positive impact on patients and help advance health care globally. That’s why I chose to partner with Paradigm Clinical Research — their commitment to honesty, integrity, and communication aligns with my values and ensures that we can conduct research in a way that benefits both our patients and the larger medical community,” said Dr. Fine. Paradigm Clinical Research is currently seeking additional principal investigators in Littleton and has a reception Wednesday, May 17, at 5:30 p.m. at Hotel Teatro for local physicians in the Denver area who are interested in supporting industry-sponsored clinical trials. To learn more about Paradigm Clinical Research or to inquire about becoming a principal investigator, please contact us.

Pediatric COVID-19 Vaccine Study

  Help pursue longer lasting protection against COVID-19 While most children do not become seriously ill from COVID-19, some do and require hospitalization. Children can still infect others and may be at risk of developing MIS-C, a rare but life-threatening inflammatory condition related to COVID-19. As new variants and subtypes continue to emerge, approval of a bivalent vaccine for children that effectively targets both current and future variants will be key for protecting them against COVID-19. This study may be an option for infants and children who: A study team member will help determine if this study is right for your child based on all participation criteria. Parents/guardians may be reimbursed for expenses related to participants’ time in the study. Contact a study member to learn more!